Balchem projects strong 2025 growth amid new product launches and robust segment performance
Q4 2024 Management View According to Ted Harris, Chairman, President, and CEO, Balchem achieved record consolidated sales of $240 million in Q4 2024, representing 4.9% growth year-over-year. Adjusted ...
MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder
MeiraGTx (MGTX) stock rose 7% after publishing promising results from the first human trial using gene therapy to treat AIPL1-associated severe retinal dystrophy in children. Across all trials so far, ...